Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Dimerix confirms ACTION3 trial remains powered for FSGS drug approval.
Dimerix Limited has confirmed its ACTION3 Phase 3 trial remains highly powered to detect a treatment effect on proteinuria, the primary endpoint.
The FDA has approved this measure for full approval of its FSGS drug DMX-200, and the company will continue the trial to completion without an interim analysis.
With adult enrollment finished and pediatric enrollment ongoing, the trial aims to secure approval for adults and adolescents.
8 Articles
Dimerix confirma que el ensayo ACTION3 se mantiene en marcha para la aprobación del medicamento por FSGS.